iBio, Inc.
IBIO · Pharmaceutical Preparations · 49.7M shares · -21%/yr ↓ buyback · EDGAR filings ↗
Reference price $1.64 · est. market cap ~$82M — last insider purchase, 2026-03-26 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D42Clinical/early-stage biotech — antibody-discovery clinical, deep losses.
Strengths
- Liquidity — current ratio 1.6 (21st)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC
- Net lossNet loss (net margin -4594.2%)
- Cash burnNegative free cash flow (-15.3M)
- Material weakness35 Table of Contents Risks Related to iBio’s Operations o We have previously identified and remediated material weaknesses in our internal controls, and cannot assure that additional weaknesses
- Exec changeRecent 8-K item 5.02 8-K ↗
- Buying back stockNet buyback — share count -21%/yr over 3y
- Insider buyingInsider buying — 4 open-market buy(s) by 3 insider(s) (cluster of 3 insiders, last 6mo) Form 4 ↗
- Notable holderHeld by 3 notable fund(s): CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, STATE STREET CORP (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-4650.5%
Net margin
-4594.2%
Return on equity
-123.5%
Return on assets
-79.3%
Revenue growth (QoQ)
77.8%
Current ratio
1.6×
Free cash flow
-$15M
Tangible book value
$8M
Cash & investments
$9M
Cash runway
2q
Stock comp / revenue
382.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-26 | Banjak Marc | Buy | 12K | $1.64 |
| 2026-03-26 | Banjak Marc | Buy | 1.4K | $1.76 |
| 2026-03-19 | Duran Felipe | Buy | 25K | $2.02 |
| 2026-03-19 | Brenner Martin | Buy | 12K | $2.02 |
| 2025-01-10 | Duran Felipe | Buy | 9.2K | $2.72 |
| 2025-01-10 | Brenner Martin | Buy | 9.2K | $2.72 |
| 2025-01-10 | Banjak Marc | Buy | 9.2K | $2.72 |
| 2025-01-10 | Arkowitz David | Buy | 18K | $2.72 |
| 2025-01-10 | Clark William D | Buy | 1.8K | $2.72 |
| 2025-01-10 | Parada Antonio Bernardino Guimaraes | Buy | 184K | $2.72 |
| 2025-01-10 | Sender Gary | Buy | 9.2K | $2.72 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07487376 ↗ | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults Overweight , Obesity | PHASE1 | Recruiting | 2027-05-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-12 | ResultsExhibits | filing ↗ |
| 2026-05-08 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-04-17 | Other | filing ↗ |
| 2026-04-08 | Reg FDOtherExhibits | filing ↗ |
| 2026-03-09 | Reg FDOtherExhibits | filing ↗ |
| 2026-02-27 | Material agreement1.02Exhibits | filing ↗ |
| 2026-02-10 | ResultsExhibits | filing ↗ |
| 2026-01-12 | Material agreement3.02Reg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-12 | 2026-05-12 | 0001104659-26-059408 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001104659-26-059416 ↗ |
| 8-K | 2026-05-08 | 2026-05-07 | 0001104659-26-057945 ↗ |
| 8-K/A | 2026-04-17 | 2026-04-08 | 0001104659-26-044969 ↗ |
| 8-K | 2026-04-08 | 2026-04-08 | 0001104659-26-040703 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001420720-26-000006 ↗ |
| 8-K | 2026-02-27 | 2026-02-23 | 0001104659-26-021654 ↗ |
| 8-K | 2026-02-10 | 2026-02-10 | 0001420720-26-000003 ↗ |
| 10-Q | 2026-02-10 | 2025-12-31 | 0001420720-26-000004 ↗ |
| 8-K | 2026-01-12 | 2026-01-08 | 0001104659-26-002940 ↗ |
| 8-K | 2025-11-21 | 2025-11-20 | 0001104659-25-114800 ↗ |
| 8-K | 2025-11-17 | 2025-11-17 | 0001420720-25-000045 ↗ |